Novartis Pharmaceuticals Corporation et al v. Lotus Pharmaceutical Co., Ltd. et al
| Novartis Pharmaceuticals Corporation and Dana-Farber Cancer Institute, Inc. |
| Lotus Pharmaceutical Co., Ltd. and Teva Pharmaceuticals Development, Inc. |
| 1:2021cv01107 |
| July 30, 2021 |
| US District Court for the District of Delaware |
| Leonard P Stark |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. § 1 |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on September 24, 2021. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Filing 17 MOTION for Pro Hac Vice Appearance of Attorney Steven M. Coyle, Nicholas A. Geiger, and Katherine M. Tassmer - filed by Teva Pharmaceuticals Development, Inc.. (Keller, Karen) |
SO ORDERED, re #17 MOTION for Pro Hac Vice Appearance of Attorney Steven M. Coyle, Nicholas A. Geiger, and Katherine M. Tassmer filed by Teva Pharmaceuticals Development, Inc. Signed by Judge Leonard P. Stark on 9/24/21. (ntl)
|
| Pro Hac Vice Attorney Nicholas A. Geiger,Katherine M. Tassmer,Steven M. Coyle for Teva Pharmaceuticals Development, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (myr) |
| Pro Hac Vice Attorney Jane M. Love for Dana-Farber Cancer Institute, Inc. and Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:21-cv-01105-LPS, 1:21-cv-01106-LPS, 1:21-cv-01107-LPS(srs) |
| Pro Hac Vice Attorneys Kyanna Sabanoglu, Anne Y. Brody, Ronald A. Lee, Sung Bin Lee for Dana-Farber Cancer Institute, Inc. and Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:21-cv-01105-LPS, 1:21-cv-01106-LPS, 1:21-cv-01107-LPS(srs) |
| Filing 16 Disclosure Statement pursuant to Rule 7.1: identifying Other Affiliate Teva Pharmaceutical Industries Ltd., Other Affiliate Teva Holdco US, Inc for Teva Pharmaceuticals Development, Inc. filed by Teva Pharmaceuticals Development, Inc.. (Hoeschen, Nathan) |
| Filing 15 ANSWER to #1 Complaint, , COUNTERCLAIM and Affirmative Defenses against All Plaintiffs by Teva Pharmaceuticals Development, Inc..(Hoeschen, Nathan) |
|
SO ORDERED, re (14 in 1:21-cv-01107-LPS, 11 in 1:21-cv-01105-LPS, 12 in 1:21-cv-01106-LPS) MOTION for Pro Hac Vice Appearance of Attorney Jane M. Love, Kyanna Sabanoglu, Sung Bin Lee, Anne Y. Brody, and Ronald A. Lee filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 9/16/21. Associated Cases: 1:21-cv-01105-LPS, 1:21-cv-01106-LPS, 1:21-cv-01107-LPS (ntl)
|
| Filing 14 MOTION for Pro Hac Vice Appearance of Attorney Jane M. Love, Kyanna Sabanoglu, Sung Bin Lee, Anne Y. Brody, and Ronald A. Lee - filed by Dana-Farber Cancer Institute, Inc., Novartis Pharmaceuticals Corporation. (Attachments: #1 Certifications for Jane M. Love, Kyanna Sabanoglu, Sung Bin Lee, Anne Y. Brody, and Ronald A. Lee)(Silver, Daniel) |
| Pro Hac Vice Attorney Gregory C. Bays for Lotus Pharmaceutical Co., Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (myr) |
|
SO ORDERED, re #13 MOTION for Pro Hac Vice Appearance of Attorney Jeremy Lowe, Steven H. Sklar, Gregory C. Bays, James W. Sanner, and Keelin D. Bielski of Leydig, Voit & Mayer, Ltd. filed by Lotus Pharmaceutical Co., Ltd. Signed by Judge Leonard P. Stark on 8/23/21. (ntl)
|
| Pro Hac Vice Attorney James W. Sanner,Jeremy Lowe for Lotus Pharmaceutical Co., Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (myr) |
| Pro Hac Vice Attorney Keelin D. Bielski for Lotus Pharmaceutical Co., Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (twk) |
| Filing 13 MOTION for Pro Hac Vice Appearance of Attorney Jeremy Lowe, Steven H. Sklar, Gregory C. Bays, James W. Sanner, and Keelin D. Bielski of Leydig, Voit & Mayer, Ltd. - filed by Lotus Pharmaceutical Co., Ltd.. (Gattuso, Dominick) |
| Filing 12 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Alvogen Emerging Markets Holding Limited, Corporate Parent Alvogen Lux Holdings S..r.l., Corporate Parent Innobic (Asia) Company Limited, Corporate Parent PTT Public Company Limited, Corporate Parent The Ministry of Finance of Thailand for Lotus Pharmaceutical Co., Ltd. filed by Lotus Pharmaceutical Co., Ltd.. (Gattuso, Dominick) |
| Filing 11 ANSWER to #1 Complaint, Answer and Affirmative Defenses By Defendant Lotus Pharmaceutical Co., Ltd. by Lotus Pharmaceutical Co., Ltd..(Gattuso, Dominick) |
|
SO ORDERED, re #10 STIPULATION TO EXTEND TIME to move, plead, or otherwise respond to the Complaint to September 20, 2021 filed by Teva Pharmaceuticals Development, Inc. Signed by Judge Leonard P. Stark on 8/9/21. (ntl)
|
| Filing 10 STIPULATION TO EXTEND TIME to move, plead, or otherwise respond to the Complaint to September 20, 2021 - filed by Teva Pharmaceuticals Development, Inc.. (Hoeschen, Nathan) |
| Case Assigned to Judge Leonard P. Stark. Please include the initials of the Judge (LPS) after the case number on all documents filed. Associated Cases: 1:21-cv-01105-LPS, 1:21-cv-01106-LPS, 1:21-cv-01107-LPS (rjb) |
| Filing 9 SUMMONS Returned Executed by Novartis Pharmaceuticals Corporation, Dana-Farber Cancer Institute, Inc.. Teva Pharmaceuticals Development, Inc. served on 7/30/2021, answer due 8/20/2021. (Joyce, Alexandra) |
| Filing 8 Summons Issued with Magistrate Consent Notice attached as to Teva Pharmaceuticals Development, Inc. on 7/30/2021. (srs) |
| Filing 7 Summons Issued with Magistrate Consent Notice attached as to Lotus Pharmaceutical Co., Ltd. on 7/30/2021. (srs) |
| Filing 6 Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Dana-Farber Cancer Institute, Inc.. (srs) |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novartis AG for Novartis Pharmaceuticals Corporation filed by Novartis Pharmaceuticals Corporation. (srs) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,973,031 ;8,222,244 ;8,575,146. (srs) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: June 14, 2021. Date of Expiration of Patents: July 13, 2025, October 29 2022, and December 2, 2030.Thirty Month Stay Deadline: 12/14/2023. (srs) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (srs) |
| Filing 1 COMPLAINT filed against Lotus Pharmaceutical Co., Ltd., and Teva Pharmaceuticals Development, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3668345.) - filed by Novartis Pharmaceuticals Corporation and Dana-Farber Cancer Institute, Inc.. (Attachments: #1 Exhibit A-C, #2 Civil Cover Sheet)(srs) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
